Project Grant HT94252510081
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This $1,574,999 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program is funding a research project at The Ohio State University titled "SLIT2 AS A NOVEL APPROACH FOR TARGETING METASTATIC BREAST CANCER". The grant, with a performance period from Jun 15, 2025 to Jun 14, 2028, supports advanced biomedical research focused on transforming healthcare for military service members and the...
This $630,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports The Ohio State University's research to develop a targeted antibody and immunotoxin combination therapy to improve treatment of T-cell lymphoma. The award period is from July 15, 2023 to July 14, 2025. This research aims to transform health care for Service Members and the American public through innovative and impactful medical solutions for the...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This Project Grant award, valued at $1,200,000.00, was provided by the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation. The grant supports research to disrupt the CX26-FAK-NANOG complex in order to attenuate cancer stem cell self-renewal and progression of triple-negative breast cancer. The 3-year project, running from May 2025 to April 2028, aims to develop innovative therapeutic strategies to address this challenging...
This $472,498 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at The Ohio State University to target the UPP1-mediated pyrimidine salvage pathway to prevent ovarian cancer recurrence. The research aims to develop innovative approaches to disease prevention, diagnosis, and treatment for conditions relevant to military personnel and the broader public. This 2-year project,...
The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027....
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $551,250.00 to The Ohio State University to support research on PPP2R1B IN DEDIFFERENTIATED LIPOSARCOMA. The project will be performed in Columbus, OH and run from Sep 30, 2023 through Sep 29, 2026. The Ohio State University has a history of conducting biomedical research and providing clinical trial coordination services to federal agencies like the National...
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
The Department of the Army Medical Command has awarded a $964,477 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Los Angeles (UCLA) for the project "TARGETING THE RAL G PROTEINS TO TREAT TRIPLE-NEGATIVE BREAST CANCER." The grant, with a period of performance from July 1, 2025 to June 30, 2028, will support advanced biomedical research to explore innovative approaches for the prevention, diagnosis, and treatment...
This $871,016 Project Grant awarded on January 1, 2024 by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the Beckman Research Institute of the City of Hope supports research on a highly tumor-specific oncolytic virus combined with a viral protein-target T cell engager for the treatment of triple-negative breast cancer. The grant aims to develop innovative therapies for this aggressive form of breast cancer that impacts military personnel and veterans. As a...